Last $14.18 USD
Change Today -0.26 / -1.80%
Volume 67.1K
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

oxford immunotec global plc (OXFD) Snapshot

Open
$14.59
Previous Close
$14.44
Day High
$14.99
Day Low
$13.91
52 Week High
03/6/14 - $25.38
52 Week Low
12/12/14 - $10.01
Market Cap
310.1M
Average Volume 10 Days
122.0K
EPS TTM
$-1.28
Shares Outstanding
21.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD IMMUNOTEC GLOBAL PLC (OXFD)

Related News

No related news articles were found.

oxford immunotec global plc (OXFD) Related Businessweek News

No Related Businessweek News Found

oxford immunotec global plc (OXFD) Details

Oxford Immunotec Global PLC, a diagnostics company, focuses on the provision of various tests in the field of immunology in the United States, Europe, Japan, and China. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. Its solution includes SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

223 Employees
Last Reported Date: 11/5/14
Founded in 2002

oxford immunotec global plc (OXFD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $330.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $255.0K
Chief Commercial Officer
Total Annual Compensation: $276.8K
Compensation as of Fiscal Year 2013.

oxford immunotec global plc (OXFD) Key Developments

Oxford Immunotec Global PLC to Report Q4, 2014 Results on Mar 03, 2015

Oxford Immunotec Global PLC announced that they will report Q4, 2014 results at 9:00 AM, GMT Standard Time on Mar 03, 2015

Oxford Immunotec Global PLC, Q4 2014 Earnings Call, Mar 03, 2015

Oxford Immunotec Global PLC, Q4 2014 Earnings Call, Mar 03, 2015

Oxford Immunotec Announces First Patients Enrolled in PROTECT Trial for T-SPOT.CMV and T-SPOT.PRT

Oxford Immunotec Global PLC announced the first patients have been enrolled in the PROTECT Study. The PROTECT study is a pivotal clinical trial designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV and T-SPOT.PRT products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXFD:US $14.18 USD -0.26

OXFD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
QIAGEN NV €22.23 EUR +0.056
View Industry Companies
 

Industry Analysis

OXFD

Industry Average

Valuation OXFD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD IMMUNOTEC GLOBAL PLC, please visit www.oxfordimmunotec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.